Originator: La Jolla Pharmaceutical Company
First marketed by: La Jolla Pharmaceutical Company, subsidiary of Innoviva Inc.
Name of FDF: Giapreza®
Original FDF: RTU solution to be diluted for continuous intravenous infusion
Mode of Action
Synthetic form of angiotensin II, a naturally occurring peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure. Angiotensin type 1 receptor agonists
Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock
Intravenous infusion formulation is still patented until 2027-12-21